Not checked for notices yet.

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

Yuanyan Tang, Haisen Yin, Xinying Zhao and 11 more

Journal of Experimental & Clinical Cancer Research · 2022

doi:10.1186/s13046-021-02214-z

Cited by papers we hold 3

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances · 2023
No notice
CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies · 2023
No notice
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges · 2022
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.